It’s important to note that antithyroid medications used to treat hyperthyroidism may cause hives or a skin rash ... symptoms that develop from neuroendocrine tumors. While considered rare ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Pancreatic cancer is one of the most aggressive cancers and has one of the lowest survival rates—only 10% after five years.

A team of researchers from the University of Chicago, in collaboration with researchers from the University of Pittsburgh, ...

U.S. medical centers are seeking FDA authorization for the compassionate use — or expanded access — of Namodenoson for ...

The DAMO PANDA can accurately detect pancreatic cancer lesions, and FDA breakthrough therapy designation aims to accelerate ...

The first screening update involved pancreatic cancer. “In patients who have a family history of pancreatic cancer or some other risk factors for it, it is recommended that they have annual ...

Researchers Shed Light on How to Predict Which Skin Cancer Patients Are Most Likely to Respond to Immunotherapy Jan. 8, 2025 — An international team of UK and US scientists discovered that the ...

ST. PAUL, Minn., April 15 (UPI) --New York University researchers say a simple, gene-based blood test has shown to be highly accurate in predicting whether some stage III melanoma patients are ...

Although conditions such as skin cancer, chronic wounds and autoimmune skin diseases are widespread, we often still don't fully understand about why they develop and how we can treat them effectively.

Changes to your moles, the appearance of a new mole or a mole that's sore or bleeding… You might think you know the symptoms of skin cancer but there are some lesser-known signs you should also look ...

You check your skin for suspicious moles and rashes, but are you paying attention to its texture? Those seemingly innocent rough patches, unusual bumps, or sudden changes in skin texture could be ...